Interaction of iron, insulin resistance, and nonalcoholic steatohepatitits

Current Gastroenterology Reports

Volumn 5, Issue 1, 2003, Pages 18-25

  Chitturi, Shivakumar ^a   George, Jacob ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; INSULIN; IRON; IRON CHELATING AGENT; TRANSFERRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DISEASE ASSOCIATION; FERRITIN BLOOD LEVEL; GENE MUTATION; HEMOCHROMATOSIS; HISTOLOGY; HUMAN; HYPERFERRITINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRON BLOOD LEVEL; IRON DEPLETION; IRON OVERLOAD; LIPID PEROXIDATION; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; PATHOGENESIS; PHLEBOTOMY; PREVALENCE; REVIEW; TRANSFERRIN BLOOD LEVEL; FATTY LIVER; LIVER; METABOLISM; PATHOPHYSIOLOGY;

FATTY LIVER; HUMANS; INSULIN RESISTANCE; IRON; IRON OVERLOAD; LIVER; OXIDATIVE STRESS;

EID: 0038621885     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-003-0005-y     Document Type: Review

References (51)

1. Ludwig J, Viggiano TR, McGill DB, et al.: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434-438.
2. Brunt EM, Janney CG, Di Bisceglie AM, et al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94:2467-2474.
3. Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying liver disease. Hepatology 1999, 29:664-669.
4. Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
5. Teli MR, James OF, Burt AD, et al.: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
6. Powell EE, Cooksley WGE, Hansen R, et al.: The natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients for up to 21 years. Hepatology 1990, 11:74-80.
7. Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
8. Ratziu V, Bonyhay L, Di Martino V, et al.: Survival, liver failure and hepatocellular carcinoma in obesity-related cirrhosis. Hepatology 2002, 35:1485-1493.
9. Bugianesi E, Leone N, Vanni E, et al.: Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
10. Zen Y, Katayanagi K, Tsuneyama K, et al.: Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001, 51:127-131.
11. Younossi ZM, Diehl AM, Ong JP: Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002, 35:746-752.
12. Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122:1649-1657.
13. Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21:27-41.
14. Tilg H, Diehl AM: Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000, 343:1467-1476.
15. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
16. Weltman MD, Farrell GC, Hall P, et al.: Hepatocyte cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27:128-133.
17. Wigg AJ, Roberts-Thomson IC, Dymock RB, et al.: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001, 48:206-211.
18. Farrell GC: Is bacterial ash the flash that ignites NASH? Gut 2001, 48:148-149.
19. Le Roith D, Zick Y: Recent advances in our understanding of insulin action and insulin resistance. Diabetes Care 2001, 24:588-597.
20. Svegliati-Baroni G, Ridolfi F, Di Sario A, et al.: Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999, 29:1743-1751.
21. Paradis V, Perlemuter G, Bonvoust F, et al.: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34:738-744.
22. Bacon BR, Farakvash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
23. Marchesini G, Brizi M, Morselli-Labate AM, et al.: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107:450-455.
24. Marchesini G, Brizi M, Bianchi G, et al.: Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
25. Knobler H, Schattner A, Zhornicki T, et al.: Fatty liver: an additional and treatable feature of the insulin resistance syndrome. QJM 1999, 92:73-9.
26. Cortez-Pinto H, Camilo ME, Baptista A, et al.: Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999, 18:353-358.
27. Tankurt E, Biberoglu S, Ellidokuz E, et al.: Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis [letter]. J Hepatol 1999, 31:963.
28. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al.: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
29. Willner IR, Waters B, Patil SR, et al.: Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001, 96:2957-2961.
30. Loguercio C, De Girolamo V, de Sio I, et al.: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol 2001, 35:568-574.
31. Comert B, Mas MR, Erdem H, et al.: Insulin resistance in nonalcoholic steatohepatitis. Dig Liver Dis 2001, 33:353-358.
32. Chitturi S, Abeygunasekera S, Farrell GC, et al.: NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
33. Pagano G, Pacini G, Musso G, et al.: Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002 35:367-372.
34. Rashid M, Roberts EA: Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000, 30:48-53.
35. Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12:1106-1110.
36. Angulo P, Keach JC, Batts KP, et al.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
37. Chitturi S, Weltman M, Farrell GC, et al.: HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology 2002, 36:142-149.
38. Khan MF, Wu X, Tipnis UR, et al.: Protein adducts of malondi-aldehyde and 4-hydroxynonenal in livers of iron loaded rats: quantitation and localization. Toxicology 2002, 173:193-201.
39. George DK, Goldwurm S, MacDonald GA, et al.: Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998, 114:311-318.
40. Bonkovsky HL, Jawaid Q, Tortorelli K, et al.: Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999, 31:421-429.
41. Younossi ZM, Gramlich T, Bacon BR, et al.: Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30:847-850.
42. Fargion S, Mattioli M, Fracanzani AL, et al.: Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:2448-2455.
43. Moirand R, Mortaji AM, Loréal L, et al.: A new syndrome of iron overload with normal transferrin saturation. Lancet 1997, 349:95-97.
44. Mendler MH, Turlin B, Moirand R, et al.: Insulin resistance-associated hepatic iron overload. Gastroenterology 1999, 117:1155-1163.
45. Macdonald GA, Powell LW: More clues to the relationship between hepatic iron and steatosis: an association with insulin resistance? Gastroenterology 1999, 117:1241-1244.
46. Guillygomarch A, Mendler MH, Moirand R, et al.: Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001, 35:344-349.
47. Facchini FS, Hua NW, Stoohs RA: Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 2002, 122:931-939.
48. Potashnik R, Kozlovsky N, Ben-Ezra S, et al.: Regulation of glucose transport and GLUT-1 expression by iron chelators in muscle cells in culture. Am J Physiol 1995, 269:E1052-E1058.
49. Fernandez-Real JM, Penarroja G, Castro A, et al.: Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 2002, 51:1000-1004.
50. Facchini FS: Effect of phlebotomy on plasma glucose and insulin concentrations. Diabetes Care 1998, 21:2190.
51. Hua NW, Stoohs RA, Facchini FS: Low iron status and enhanced insulin sensitivity in lacto-ovo vegetarians. Br J Nutr 2001, 86:515-519.